AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Exploratory Study to Assess the Pharmacokinetics of AZD5985
- First Posted Date
- 2008-11-27
- Last Posted Date
- 2009-06-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT00799331
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A Feasibility Study to Collect Data in Patients With Haemophilia
Completed
- Conditions
- Hemophilia
- Interventions
- Other: Laboratory variables
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2009-07-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT00798499
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
European Survey of Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB)
Completed
- Conditions
- Non-variceal Upper Gastrointestinal BleedingGastrointestinal UlcerGastrointestinal Hemorrhage
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2009-12-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2500
- Registration Number
- NCT00797641
- Locations
- 🇹🇷
Research site, Mersin, Turkey
Safety, Tolerability, and Pharmacokinetics of AZD7268 After Single Ascending Oral Doses in Healthy Subjects
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2009-08-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT00796965
- Locations
- 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States
Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US
Completed
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2010-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 552
- Registration Number
- NCT00795093
- Locations
- 🇺🇸
Research Site, West Jordan, Utah, United States
Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2009-06-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00791752
- Locations
- 🇸🇪
Research Site, Gotteborg, Sweden
To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2009-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT00790153
- Locations
- 🇺🇸
Research Site, Chula Vista, California, United States
Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients
Phase 3
Completed
- Conditions
- Major Depressive DisorderTreatment Resistant Depression
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 688
- Registration Number
- NCT00789854
- Locations
- 🇬🇧
Research Site, Winsford, United Kingdom
Determine the Effect of Multiple Doses of AZD7325, CYP Study
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2008-11-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00790114
The Use of a Forecasting System for Predicting Exacerbations of COPD
Early Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Behavioral: COPD self care adviceBehavioral: Poor weather forecast warning
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2010-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 98
- Registration Number
- NCT00788645
- Locations
- 🇬🇧
Research Site, Exeter, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath